LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Protagonist Therapeutics Inc

Open

SectorHealthcare

44.73 0.68

Overview

Share price change

24h

Current

Min

43.96

Max

45.14

Key metrics

By Trading Economics

Income

-143M

-12M

Sales

-142M

28M

P/E

Sector Avg

58.039

56.602

EPS

-0.19

Profit margin

-41.153

Employees

124

EBITDA

-146M

-19M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+52.67% upside

Dividends

By Dow Jones

Next Earnings

4 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-14M

2.8B

Previous open

44.05

Previous close

44.73

News Sentiment

By Acuity

50%

50%

173 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Protagonist Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

10 Mar 2025, 13:59 UTC

Major Market Movers

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Peer Comparison

Price change

Protagonist Therapeutics Inc Forecast

Price Target

By TipRanks

52.67% upside

12 Months Forecast

Average 67.8 USD  52.67%

High 82 USD

Low 38 USD

Based on 10 Wall Street analysts offering 12 month price targets forProtagonist Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

9

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

43.62 / 44.27Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

173 / 382 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.